Shared on 05 Dec 25

Fair value Increased 0.86%

JNJ: Future Reorganization And Litigation Outcomes Will Shape Risk Reward Balance

The analyst price target for Johnson & Johnson has been nudged higher, with fair value rising from approximately $200.82 to $202.54 per share, as analysts highlight slightly stronger long term revenue growth, modestly higher profit margins, and a richer future P/E multiple supported by an improving innovation pipeline and portfolio reshaping efforts. Analyst Commentary Recent research updates reflect a broadly constructive stance on Johnson & Johnson, with a growing number of firms highlighting improving fundamentals, a stronger growth profile, and a more compelling risk reward setup following the latest results and guidance.

Shared on 21 Nov 25

Fair value Increased 0.64%

JNJ: Upcoming Business Reorganization and Legal Risks Will Influence Future Performance

Johnson & Johnson's analyst price target has increased slightly from $199.56 to $200.82, as analysts cite stronger-than-expected sector performance and a constructive long-term industry outlook, which support the adjustment. Analyst Commentary Recent analyst commentary on Johnson & Johnson highlights a variety of perspectives related to the company's valuation, strategic direction, and future growth potential.

Shared on 05 Nov 25

Fair value Increased 0.77%

JNJ: Upcoming Portfolio Shifts and Legal Uncertainties Will Shape Risk-Reward Balance

Johnson & Johnson's fair value estimate has increased by $1.52 to $199.56, as analysts point to improving core growth metrics, recent strong quarterly results, and expectations for higher margins following portfolio changes. Analyst Commentary Recent Street research reveals a mix of optimism and caution among analysts following Johnson & Johnson’s latest results, portfolio changes, and evolving sector dynamics.

Shared on 22 Oct 25

Fair value Increased 6.97%

Analysts have raised their fair value price target for Johnson & Johnson from approximately $185.13 to $198.03. They cite robust quarterly results, upcoming product launches, and anticipated growth and margin improvements from the company's business transformation initiatives as key reasons for the adjustment.

Shared on 08 Oct 25

Fair value Increased 3.05%

Johnson & Johnson's analyst-derived fair value price target has increased by approximately $5.48 to $185.13. Analysts point to stronger recent biopharma performance, improved confidence in growth following the Stelara expiry, and moderating regulatory concerns as key drivers of the upward revision.

Shared on 24 Sep 25

Fair value Increased 1.22%

Analysts raised Johnson & Johnson’s price target to $179.64, reflecting confidence in robust performance of its Innovative Medicine portfolio and pipeline assets, improved earnings guidance, and resilient management of patent challenges, partly offset by regulatory uncertainty. Analyst Commentary Bullish analysts view Johnson & Johnson's handling of the Stelara loss of exclusivity as strong, emphasizing confidence in new growth led by its Innovative Medicine business and existing product portfolio (Tremfya, Darzalex, Spravato, Caplyta).

Shared on 04 Sep 25

Johnson & Johnson’s unchanged analyst price target reflects balanced sentiment, with bulls encouraged by Q2 earnings strength, improved guidance, and ongoing growth expectations, while bears flag regulatory and clinical trial risks, resulting in fair value holding steady at $177.47. Analyst Commentary Bullish analysts raised price targets following Johnson & Johnson’s Q2 earnings beat, with expectations for continued top- and bottom-line growth into 2026 and potential to exceed guidance for Innovative Medicine sales CAGR.

Shared on 08 May 25

Fair value Increased 4.92%

Shared on 30 Apr 25

Fair value Decreased 0.077%

Shared on 23 Apr 25

Fair value Decreased 0.65%

AnalystConsensusTarget has decreased shares outstanding growth rate from 0.0% to -0.0%.

Shared on 17 Apr 25

Fair value Increased 0.88%

AnalystConsensusTarget has increased revenue growth from 3.3% to 3.6%.

Shared on 09 Apr 25

Fair value Decreased 0.80%

AnalystConsensusTarget has increased revenue growth from 2.9% to 3.3%, increased profit margin from 21.0% to 23.3% and increased shares outstanding growth rate from 0.0% to 0.0%.

Shared on 02 Apr 25

Fair value Increased 0.64%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Increased 0.089%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 11 Mar 25

Fair value Increased 2.88%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Analyst Commentary Drives Higher Valuation Targets for Johnson & Johnson Amid Positive Company Developments

JNJ: Future Reorganization And Litigation Outcomes Will Shape Risk Reward Balance

JNJ: Upcoming Business Reorganization and Legal Risks Will Influence Future Performance

JNJ: Upcoming Portfolio Shifts and Legal Uncertainties Will Shape Risk-Reward Balance

Shared on 22 Oct 25

Shared on 08 Oct 25

Shared on 24 Sep 25

Shared on 04 Sep 25

Shared on 08 May 25

Shared on 30 Apr 25

Shared on 23 Apr 25

Shared on 17 Apr 25

Shared on 09 Apr 25

Shared on 02 Apr 25

Shared on 26 Mar 25

Shared on 19 Mar 25

Shared on 11 Mar 25